-
Je něco špatně v tomto záznamu ?
Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective analysis from the European Society for Blood and Marrow Transplantation (EBMT)
J. Schetelig, LC. de Wreede, NS. Andersen, C. Moreno, M. van Gelder, A. Vitek, M. Karas, M. Michallet, M. Machaczka, M. Gramatzki, D. Beelen, J. Finke, J. Delgado, L. Volin, J. Passweg, P. Dreger, N. Schaap, E. Wagner, A. Henseler, A. van Biezen,...
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, multicentrická studie
PubMed
28589551
DOI
10.1111/bjh.14791
Knihovny.cz E-zdroje
- MeSH
- chronická lymfatická leukemie mortalita terapie MeSH
- dospělí MeSH
- Kaplanův-Meierův odhad MeSH
- Karnofského skóre MeSH
- lidé středního věku MeSH
- lidé MeSH
- odborná praxe statistika a číselné údaje MeSH
- poskytování zdravotní péče statistika a číselné údaje MeSH
- příprava pacienta k transplantaci metody MeSH
- recidiva MeSH
- registrace MeSH
- retrospektivní studie MeSH
- rizikové faktory MeSH
- senioři MeSH
- transplantace hematopoetických kmenových buněk metody MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- Geografické názvy
- Evropa epidemiologie MeSH
The best approach for allogeneic haematopoietic stem cell transplantations (alloHCT) in patients with chronic lymphocytic leukaemia (CLL) is unknown. We therefore analysed the impact of procedure- and centre-related factors on 5-year event-free survival (EFS) in a large retrospective study. Data of 684 CLL patients who received a first alloHCT between 2000 and 2011 were analysed by multivariable Cox proportional hazards models with a frailty component to investigate unexplained centre heterogeneity. Five-year EFS of the whole cohort was 37% (95% confidence interval [CI], 34-42%). Larger numbers of CLL alloHCTs (hazard ratio [HR] 0·96, P = 0·002), certification of quality management (HR 0·7, P = 0·045) and a higher gross national income per capita (HR 0·4, P = 0·04) improved EFS. In vivo T-cell depletion (TCD) with alemtuzumab compared to no TCD (HR 1·5, P = 0·03), and a female donor compared to a male donor for a male patient (HR 1·4, P = 0·02) had a negative impact on EFS, but not non-myeloablative versus more intensive conditioning. After correcting for patient-, procedure- and centre-characteristics, significant variation in centre outcomes persisted. In conclusion, further research on the impact of centre and procedural characteristics is warranted. Non-myeloablative conditioning appears to be the preferable approach for patients with CLL.
BMT Unit Department of Haematology Rigshospitalet Copenhagen Denmark
Bone Marrow Transplantation Centre University Hospital Eppendorf Hamburg Germany
Centre Hospitalier Lyon Sud Hématologie Lyon France
Department for Haematology University Hospital Basel Switzerland
Department of Biology University of Tor Vergata Rome Italy
Department of Bone Marrow Transplantation University Hospital Essen Germany
Department of Haematology Institute of Haematology and Blood Transfusion Prague Czech Republic
Department of Haematology Oncology Charles University Hospital Pilsen Czech Republic
Department of Medicine Haematology Oncology University of Freiburg Freiburg Germany
Hematologia Hospital de la Santa Creu i Sant Pau Barcelona Spain
Institute of Haematology and Oncology Department of Haematology Hospital Clinic Barcelona Spain
Medical Department 1 University Hospital of the Technical University Dresden Dresden Germany
Medizinische Klinik u Poliklinik 5 University of Heidelberg Heidelberg Germany
Radboud University Medical Centre Nijmegen the Netherlands
University Medical Centre Maastricht Maastricht The Netherlands
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17030768
- 003
- CZ-PrNML
- 005
- 20171025115354.0
- 007
- ta
- 008
- 171025s2017 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/bjh.14791 $2 doi
- 035 __
- $a (PubMed)28589551
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Schetelig, Johannes $u Medical Department I, University Hospital of the Technical University Dresden, Dresden, Germany. DKMS Clinical Trials Unit, Dresden, Germany.
- 245 10
- $a Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective analysis from the European Society for Blood and Marrow Transplantation (EBMT) / $c J. Schetelig, LC. de Wreede, NS. Andersen, C. Moreno, M. van Gelder, A. Vitek, M. Karas, M. Michallet, M. Machaczka, M. Gramatzki, D. Beelen, J. Finke, J. Delgado, L. Volin, J. Passweg, P. Dreger, N. Schaap, E. Wagner, A. Henseler, A. van Biezen, M. Bornhäuser, S. Iacobelli, H. Putter, SO. Schönland, N. Kröger, . ,
- 520 9_
- $a The best approach for allogeneic haematopoietic stem cell transplantations (alloHCT) in patients with chronic lymphocytic leukaemia (CLL) is unknown. We therefore analysed the impact of procedure- and centre-related factors on 5-year event-free survival (EFS) in a large retrospective study. Data of 684 CLL patients who received a first alloHCT between 2000 and 2011 were analysed by multivariable Cox proportional hazards models with a frailty component to investigate unexplained centre heterogeneity. Five-year EFS of the whole cohort was 37% (95% confidence interval [CI], 34-42%). Larger numbers of CLL alloHCTs (hazard ratio [HR] 0·96, P = 0·002), certification of quality management (HR 0·7, P = 0·045) and a higher gross national income per capita (HR 0·4, P = 0·04) improved EFS. In vivo T-cell depletion (TCD) with alemtuzumab compared to no TCD (HR 1·5, P = 0·03), and a female donor compared to a male donor for a male patient (HR 1·4, P = 0·02) had a negative impact on EFS, but not non-myeloablative versus more intensive conditioning. After correcting for patient-, procedure- and centre-characteristics, significant variation in centre outcomes persisted. In conclusion, further research on the impact of centre and procedural characteristics is warranted. Non-myeloablative conditioning appears to be the preferable approach for patients with CLL.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a poskytování zdravotní péče $x statistika a číselné údaje $7 D003695
- 650 _2
- $a Evropa $x epidemiologie $7 D005060
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a transplantace hematopoetických kmenových buněk $x metody $7 D018380
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a Kaplanův-Meierův odhad $7 D053208
- 650 _2
- $a Karnofského skóre $7 D017567
- 650 _2
- $a chronická lymfatická leukemie $x mortalita $x terapie $7 D015451
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a odborná praxe $x statistika a číselné údaje $7 D011364
- 650 _2
- $a recidiva $7 D012008
- 650 _2
- $a registrace $7 D012042
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a příprava pacienta k transplantaci $x metody $7 D019172
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a de Wreede, Liesbeth C $u DKMS Clinical Trials Unit, Dresden, Germany. Department of Medical Statistics & Bioinformatics, Leiden University Medical Centre, Leiden, The Netherlands.
- 700 1_
- $a Andersen, Niels S $u BMT Unit Department of Haematology, Rigshospitalet, Copenhagen, Denmark. $7 gn_A_00006089
- 700 1_
- $a Moreno, Carol $u Hematologia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
- 700 1_
- $a van Gelder, Michel $u University Medical Centre Maastricht, Maastricht, The Netherlands.
- 700 1_
- $a Vitek, Antonin $u Department of Haematology, Institute of Haematology and Blood Transfusion, Prague, Czech Republic.
- 700 1_
- $a Karas, Michal $u Department of Haematology/Oncology, Charles University Hospital, Pilsen, Czech Republic.
- 700 1_
- $a Michallet, Mauricette $u Centre Hospitalier Lyon-Sud - Hématologie, Lyon, France.
- 700 1_
- $a Machaczka, Maciej $u Haematology Centre Karolinska and Department of Medicine at Huddinge, Karolinska Institutet, Stockholm, Sweden.
- 700 1_
- $a Gramatzki, Martin $u Division of Stem Cell Transplantation and Immunotherapy, University Hospital Schleswig-Holstein, Kiel, Germany.
- 700 1_
- $a Beelen, Dietrich $u Department of Bone Marrow Transplantation, University Hospital, Essen, Germany.
- 700 1_
- $a Finke, Jürgen $u Department of Medicine - Haematology, Oncology, University of Freiburg, Freiburg, Germany.
- 700 1_
- $a Delgado, Julio $u Institute of Haematology & Oncology, Department of Haematology, Hospital Clinic, Barcelona, Spain.
- 700 1_
- $a Volin, Liisa $u Stem Cell Transplantation Unit, Helsinki University Hospital Comprehensive Cancer Centre, Helsinki, Finland.
- 700 1_
- $a Passweg, Jakob $u Department for Haematology, University Hospital, Basel, Switzerland.
- 700 1_
- $a Dreger, Peter $u Medizinische Klinik u. Poliklinik V, University of Heidelberg, Heidelberg, Germany.
- 700 1_
- $a Schaap, Nicolaas $u Radboud University Medical Centre, Nijmegen, the Netherlands.
- 700 1_
- $a Wagner, Eva $u University Medical Centre Mainz, Mainz, Germany.
- 700 1_
- $a Henseler, Anja $u Department of Medical Statistics & Bioinformatics, Leiden University Medical Centre, Leiden, The Netherlands.
- 700 1_
- $a van Biezen, Anja $u Department of Medical Statistics & Bioinformatics, Leiden University Medical Centre, Leiden, The Netherlands.
- 700 1_
- $a Bornhäuser, Martin $u Medical Department I, University Hospital of the Technical University Dresden, Dresden, Germany.
- 700 1_
- $a Iacobelli, Simona $u Department of Biology, University of Tor Vergata, Rome, Italy.
- 700 1_
- $a Putter, Hein $u Department of Medical Statistics & Bioinformatics, Leiden University Medical Centre, Leiden, The Netherlands.
- 700 1_
- $a Schönland, Stefan O $u Department of Haematology, Institute of Haematology and Blood Transfusion, Prague, Czech Republic.
- 700 1_
- $a Kröger, Nicolaus $u Bone Marrow Transplantation Centre, University Hospital Eppendorf, Hamburg, Germany.
- 700 1_
- $a ,
- 773 0_
- $w MED00009374 $t British journal of haematology $x 1365-2141 $g Roč. 178, č. 4 (2017), s. 521-533
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28589551 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20171025 $b ABA008
- 991 __
- $a 20171025115436 $b ABA008
- 999 __
- $a ok $b bmc $g 1254361 $s 991795
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 178 $c 4 $d 521-533 $e 20170607 $i 1365-2141 $m British journal of haematology $n Br J Haematol $x MED00009374
- LZP __
- $a Pubmed-20171025
